[go: up one dir, main page]

MX2008001520A - Composiciones de tizanidina y metodos de tratamiento usando las composiciones. - Google Patents

Composiciones de tizanidina y metodos de tratamiento usando las composiciones.

Info

Publication number
MX2008001520A
MX2008001520A MX2008001520A MX2008001520A MX2008001520A MX 2008001520 A MX2008001520 A MX 2008001520A MX 2008001520 A MX2008001520 A MX 2008001520A MX 2008001520 A MX2008001520 A MX 2008001520A MX 2008001520 A MX2008001520 A MX 2008001520A
Authority
MX
Mexico
Prior art keywords
compositions
tizanidine
treatment
methods
patient
Prior art date
Application number
MX2008001520A
Other languages
English (en)
Inventor
Moshe Flashner-Barak
Alon Gavin Judelman
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2008001520A publication Critical patent/MX2008001520A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se refiere a metodos para tratar la espasticidad en un paciente que tiene una enfermedad neurologica que comprende administrar a un paciente que necesita dicho tratamiento una formulacion de tizanidina que proporciona una concentracion de tizanidina en sangre de por lo menos 900 pg/ml durante cinco horas, en donde la formulacion se administra antes de la hora de dormir.
MX2008001520A 2005-08-01 2006-08-01 Composiciones de tizanidina y metodos de tratamiento usando las composiciones. MX2008001520A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70473105P 2005-08-01 2005-08-01
US81907406P 2006-07-06 2006-07-06
PCT/US2006/030273 WO2007016676A1 (en) 2005-08-01 2006-08-01 Tizanidine compositions and methods of treatment using the compositions

Publications (1)

Publication Number Publication Date
MX2008001520A true MX2008001520A (es) 2008-04-07

Family

ID=37440863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001520A MX2008001520A (es) 2005-08-01 2006-08-01 Composiciones de tizanidina y metodos de tratamiento usando las composiciones.

Country Status (11)

Country Link
US (1) US20070078174A1 (es)
EP (1) EP1909787A1 (es)
JP (1) JP2008540688A (es)
KR (1) KR20080028480A (es)
AU (1) AU2006275405A1 (es)
BR (1) BRPI0614907A2 (es)
CA (1) CA2612480A1 (es)
EA (1) EA200800397A1 (es)
IL (1) IL186325A0 (es)
MX (1) MX2008001520A (es)
WO (1) WO2007016676A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
US20080194655A1 (en) * 2007-02-09 2008-08-14 Scott Bull Zero order controlled release compositions of tizanidine
KR101490253B1 (ko) * 2007-08-10 2015-02-05 엘지전자 주식회사 무선 통신 시스템에서의 제어정보 전송 및 수신 방법
TR200708925A1 (tr) 2007-12-26 2009-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan flurbiprofen ve kas gevşetici kombinasyonları
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
CN101780075B (zh) * 2009-01-16 2013-10-30 四川科瑞德制药有限公司 一种治疗失眠的联合用药物
US20120058962A1 (en) * 2009-05-20 2012-03-08 Lingual Conseqna Pty Ltd. Buccal and/or sublingual therapeutic formulation
JP6513702B2 (ja) * 2014-12-25 2019-05-15 株式会社ダイセル 超速崩壊錠剤及びその製造方法
WO2020202192A1 (en) 2019-03-29 2020-10-08 Cipla Limited Pharmaceutical combination formulations comprising tizanidine, resveratrol and piperine
CN115400123B (zh) * 2021-05-26 2025-04-11 四川科瑞德制药股份有限公司 一种替扎尼定液体制剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
WO1993012769A1 (fr) * 1991-12-24 1993-07-08 Yamanouchi Pharmaceutical Co., Ltd. Preparation se desagrageant dans la bouche et elaboration de cette preparation
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2003005951A2 (en) * 2001-07-10 2003-01-23 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
NZ540106A (en) * 2002-11-12 2008-03-28 Teva Pharma Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally
WO2005046648A1 (en) * 2003-11-12 2005-05-26 Glenmark Pharmaceuticals Ltd. Extended release pharmaceutical dosage forms comprising alpha-2 agonist tizanidine

Also Published As

Publication number Publication date
EP1909787A1 (en) 2008-04-16
JP2008540688A (ja) 2008-11-20
IL186325A0 (en) 2008-02-09
KR20080028480A (ko) 2008-03-31
US20070078174A1 (en) 2007-04-05
AU2006275405A1 (en) 2007-02-08
BRPI0614907A2 (pt) 2011-04-19
EA200800397A1 (ru) 2008-08-29
WO2007016676A1 (en) 2007-02-08
CA2612480A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
TW200612987A (en) Combination treatment for non-hematologic malignancies
LUC00011I1 (es)
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
ATE372774T1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
BRPI0411010A (pt) métodos para manter ou aumentar o número de glóbulos brancos do sangue em um paciente com cáncer submetido a tratamento quimioterapêutico para cáncer, para manter ou aumentar o número de plaquetas no sangue em um paciente com cáncer submetido a tratamento quimioterapêutico para cáncer e para reduzir a toxicidade gastrintestinal em um paciente com cáncer resultante de um agente quimioterapêutico anti-cáncer, composição farmacêutica, e, kit
BRPI0410576A (pt) composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo
BR0317772A (pt) Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento
WO2008133952A3 (en) Transmucosal treatment with fentanyl in patients with mucositis
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
MD3503G2 (ro) Metodă de cupare a sindromului algic
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
BRPI0404771A (pt) medicamento e tratamento para dores em geral e outros sintomas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal